Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

By sjmartinez • February 11, 2023

Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 10;188(2):198-207. doi: 10.1093/bjd/ljac040. PMID: 36763857.

Tags: Dermatology, Publications

Measles Resurgence: What Every Dermatologist Should Know

Freeman E, Li C, Castillo D, Ahuja S, Chiu YE, Elewski B, Goh C, Hu J, Rosmarin D, Trinidad J, Rosenbach M. Measles Resurgence: What[...]

Collagen V regulates renal function after kidney injury and can be pharmacologically targeted to enhance kidney repair in mice

Su L, Sun Q, Li Y, Alvarez JF, Tao B, Zhang G, Gu Y, Hanudel MR, Espinoza A, Zhang L, Pan C, Hilser JR, Hartiala[...]

Genome-wide DNA methylation patterns in Daphnia magna are not significantly associated with age

Liu R, Morselli M, Yampolsky LY, Peshkin L, Pellegrini M. Genome-wide DNA methylation patterns in Daphnia magna are not significantly associated with age. Epigenetics Chromatin.[...]